Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: June 30, 2026
Reporting Period: Second Quarter 2026 (Newsletter Release)
Business Overview: The Company is a Delaware corporation focused on laboratory developed tests, specifically highlighting the commercialization of CyPath® Lung. It is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K serves as a notification of a newsletter release rather than a financial statement.
Material Changes
Item 8.01 (Other Events): On June 30, 2026, the Company released its "1st Edition, 2nd Quarter 2026" newsletter. This document provides an overview of recent developments but does not detail specific quantitative material changes in financial performance within the text of the 8-K itself.
Guidance, Outlook, and Risks
- Outlook: The Company's forward-looking statements focus on the ability to successfully commercialize CyPath® Lung.
- Risks: Key risks include the regulatory environment for laboratory developed tests and other factors previously disclosed in the Annual Report on Form 10-K for the year ended December 31, 2025.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to various uncertainties. The Company does not undertake an obligation to update these statements except as required by law.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Company Newsletter) for specific details on recent developments and operational updates not included in the 8-K summary.
- Verify the regulatory status and commercialization progress of CyPath® Lung as referenced in the forward-looking statements.
- Consult the most recent Form 10-K (Year ended Dec 31, 2025) and subsequent Form 10-Q filings for actual financial data, as this 8-K contains no financial metrics.
- Monitor for updates on the regulatory environment for laboratory developed tests, identified as a primary risk factor.